Greenwich LifeSciences, Inc.
For the period ended Dec 31, 2024. Filed Apr 15, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 15, 2025
GLSI$16.52+8.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
| 2024 | 2023 | |
|---|---|---|
| Operating activities: | ||
| Net loss | $(15,788,809) | $(8,891,803) |
| Adjustments required to reconcile net loss to net cash used in operating activities: | ||
| Amortization | 3,612 | 3,612 |
| Stock-based compensation | 7,253,327 | 2,378,088 |
| Changes in operating assets and liabilities: | ||
| Accounts payable | 921,219 | 35,472 |
| Deferred compensation | 306,281 | |
| Unreimbursed expenses (accrued) | 37,827 | (3,971) |
| Net cash used in operating activities | (7,266,543) | (6,478,602) |
| Financing activities: | ||
| Sale of common stock via ATM program, net of costs | 1,869,111 | |
| Sale of common stock via Private Placement, net of costs | 2,499,998 | — |
| Net cash provided by (used in) financing activities | 4,369,109 | — |
| Net increase (decrease) in cash | (2,897,434) | (6,478,602) |
| Cash, beginning of period | 6,989,424 | 13,468,026 |
| Cash, end of period | $4,091,990 | $6,989,424 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.